Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0699790 (colon cancer)
 28,837 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

In a large, population based, epidemiological study of colorectal cancer, The Melbourne Colorectal Cancer Study, several etiological factors were investigated. Persons' recent life changes, as well as the degree of upset they experienced as a result of these changes, were included. Interviews with 715 histologically confirmed new cases of colorectal cancer occurring over a 12-month period in Melbourne, Australia, and with 727 age and sex matched community controls were conducted. As one of the methods of assessing any effect of recall bias, 179 hospital controls were also investigated. Major illness or death of a family member, major family problems and major work problems were found to be significantly more common for cases over the 5 years preceding diagnosis compared to controls. Cases also reported being significantly more upset with their recent life changes than did controls. No significant differences in results were found between males and females, or between colon cancer and rectal cancer patients. Although the possibility of recall bias, was not completely controlled for in this study, it was probably not an important factor in explaining case-control differences. Recent life changes, and their perceptions, may have significance in the development of large bowel cancer.
 ...
PMID:Recent life change and large bowel cancer. Data from the Melbourne Colorectal Cancer Study. 198 59

Fluorouracil (5-FU) is still the mainstay of adjuvant treatment for colorectal cancer. Two trials have shown a disease-free and overall survival benefit for 5-FU combined with levamisole in patients with node-positive colon cancer. This regimen is fairly well tolerated and devoid of long-term sequelae, and is now considered standard treatment for node-positive colon cancer. One trial showed a modest improvement in disease-free survival for the semustine/vincristine/5-FU combination; the leukemogenicity and renal toxicity caused by semustine have prevented this regimen from being adopted. Although administering 5-FU directly into the portal vein may improve disease-free survival, most trials have failed to demonstrate a reduction in the incidence of hepatic metastases. This technique, therefore, remains investigational. Several trials in rectal cancer show an advantage for 5-FU combined with semustine and radiation therapy in terms of disease-free survival, overall survival, or both; the contribution of semustine has been questioned and is currently being investigated. In patients with metastatic disease, hepatic arterial infusion of floxuridine produces a higher objective response rate than intravenous administration, but has not resulted in a survival benefit; hepatobiliary toxicity limits the duration of therapy. Biochemical modulation of 5-FU with leucovorin increases the response rate produced by 5-FU alone; a survival benefit has also been observed. N-(phosphonacetyl)-L-aspartate has shown initial promise in combination with high-dose 5-FU infusions. Among the many new drugs tested, only tauromustine seems worthy of further study.
 ...
PMID:Current treatment approaches in colorectal cancer. 199 27

Relationships between reproductive factors and risk of colorectal cancer were examined in a population-based prospective study in Norway. Available for analysis were 831 cases (581 colon cancer, 250 rectal cancer) diagnosed in a cohort of 63,090 women, surveyed in 1956-1959 and followed through 1980. Overall, the analyses showed no strong effects of reproductive factors. In particular, high parity was not associated with reduced risk, and late age at first or last birth was not associated with an increased overall risk. However, in age-specific analyses of colon cancer, adverse effects of late age at first birth and late age at last birth were observed in women with cancer diagnosed before the age of 60. A non-significant overall excess risk in parous compared to nulliparous women was strongest for women with a cancer diagnosis before the age of 50 years. Having had many abortions was associated with increased risk for all sub-sites. Neither age at menarche nor age at menopause were related to risk of colorectal cancer. The results suggest that reproductive factors, which are of importance in the etiology of cancer of the breast and genital organs in women, are not similarly related to risk of colorectal cancer.
 ...
PMID:Is the incidence of colorectal cancer related to reproduction? A prospective study of 63,000 women. 199 46

The substantial recurrence rate of colorectal cancer following potentially curative resection has fuelled the search for effective adjuvant therapy. Previous trials using 5-fluorouracil (5-FU) as a single agent or in combination chemotherapy regimens have not demonstrated meaningful benefits, an impression reflected in the results of a meta-analysis encompassing large patient numbers. Newer developments utilizing intraportal chemotherapy and the combination of 5-FU and levamisole have resulted in lower recurrence rates and improved survival in patients with colon cancer. In advanced disease, the biochemical modulation of 5-FU by Leucovorin has been shown to prolong survival in some studies. Combined chemotherapy and radiotherapy or chemotherapy alone have showed promising results in rectal cancer. These developments have now been incorporated into ongoing trials.
 ...
PMID:Adjuvant therapy of colorectal cancer: an overview. 199 78

The chemosensitivities of 62 human colon cancer tissues, 67 rectal cancer tissues and 31 tumor-adjacent normal mucosal tissues were determined using the in vitro succinate dehydrogenase inhibition (SDI) test. These tissues obtained at the time of surgery were exposed to carboquone (CQ), adriamycin (ADM), mitomycin C (MMC), aclacinomycin A (ACR), cisplatin (DDP) and 5-fluorouracil (5-FU). The chemosensitivity was considered as positive when succinate dehydrogenase (SD) activity of the drug-treated cells decreased to below 50% of that of control cells, on day 3 of exposure. Decrease in the SD activity was noted in the colon cancer tissues, compared to the rectal cancer tissues, exposed to six antitumor drugs and in particular, to CQ (p less than 0.05), DDP (p less than 0.01) and ACR (p less than 0.05, one-sided paired t test). Decrease in the SD activity was noted in the tumor tissues, compared to the tumor-adjacent normal tissues, exposed to CQ, MMC and ACR (p less than 0.01). The sensitive rates were higher in the colon cancer tissues than the rectal cancer tissues, against all six antitumor drugs. Our findings show that the rectal cancer tissues are resistant to antitumor drugs, compared to the colon cancer tissues in vitro. When selecting antitumor drugs to treat patients with a rectal cancer, the assessment for chemosensitivity of the related tissues is crucial.
 ...
PMID:Human colon cancer tissues are more sensitive than rectal cancer tissues to antitumor drugs in vitro. 199 40

Mortality from colon and rectum cancer has been reviewed in three cohorts working in 1933-1982 in two plants manufacturing and polymerizing acrylate monomers. The two cohorts with later dates of hire showed no excess mortality. In the earliest cohort, excess colon cancer seemed restricted to men employed extensively in the early 1940s in jobs entailing the highest exposures to vapor-phase ethyl acrylate (EA) and methyl methacrylate (MMA) monomer and volatile by-products of the EA/MMA polymerization process. The excess mortality appeared only some two decades after the equivalent of three years' employment in jobs with the most intense exposures. A smaller elevation in colon cancer mortality also appeared in a low-exposure group in the early cohort. Rectal cancer mortality was elevated in the same categories that showed excess rates of colon cancer death. Because of the lower rates, the rectal cancer results are more imprecise.
 ...
PMID:Mortality from cancer of the colon or rectum among workers exposed to ethyl acrylate and methyl methacrylate. 204 10

Incidence rates of cancers of the colon, rectum, female breast, and prostate were compared among native Chinese (Shanghai), Chinese-American, and American populations. Americans had fourfold higher age-adjusted rates of colon cancer, and twofold higher rates of rectal cancer than Chinese, which is consistent with elevated per capita intake of fat and lower intake of cereals and vegetables in the US. Incidence rates of colon and rectal cancers in Chinese-Americans were nearly equal to the American rates, suggesting that the risk for tumour development in the lower intestinal tract is rapidly increased with transition to the US diet. Rates of prostate cancer and postmenopausal breast cancer were 26-fold and tenfold higher in Americans than in Chinese, whereas the rates for Chinese-Americans were intermediate. Environmental factors such as dietary fat apparently had a more gradual effect in promoting cancers of the breast and prostate relative to their influence on neoplasms of the lower intestinal tract.
 ...
PMID:Comparative epidemiology of cancers of the colon, rectum, prostate and breast in Shanghai, China versus the United States. 206 47

The National Institutes of Health Consensus Development Conference on Adjuvant Therapy for Patients With Colon and Rectum Cancer brought together surgeons, medical oncologists, radiation oncologists, gastroenterologists, other health care providers, and the public to address the issues regarding adjuvant therapy for colon and rectum cancer. Following 1 1/2 days of presentations by experts and discussion by the audience, a consensus panel weighed the evidence and prepared a consensus statement. Among their findings, the panel recommended that patients with Stage III colon cancer should receive adjuvant therapy with 5-fluorouracil (5-FU) and levamisole. Specific adjuvant therapy is not recommended for Stage II colon cancer patients outside of clinical trials. For rectal cancer, the panel recommended that adjuvant therapy combining chemotherapy and radiation therapy improves local control and survival for Stage II and III patients. The most effective combination at present appears to be 5-FU, methyl-CCNU, and high-dose pelvic irradiation. However, the use of methyl-CCNU outside of clinical trials is discouraged because of documented toxicities. The panel concluded that patients with Stage I colon and rectal cancers are at low risk of recurrence and do not warrant adjuvant therapy. The panel also recommended that the American Joint Committee on Cancer system for classifying stages of colon and rectal cancer, known as the TNM system, become the standard measurement used in clinical trials and in clinical practice.
 ...
PMID:Adjuvant therapy for patients with colon and rectum cancer. 207 98

Clinical studies on adjuvant chemotherapy in colorectal cancer started 30 years ago, but some proof of its effectiveness did not come until recently. Only randomized prospective studies can provide definite evidence in this regard. Obviously, the potential value of an effective adjuvant treatment for a frequent disease such as colorectal cancer is enormous. Randomized studies had failed to provide evidence in favour of adjuvant chemotherapy in colon cancer until a recently reported study on 5-fluorouracil and levamisole. As of today, the latter regimen may be considered as the reference one for adjuvant chemotherapy in Dukes C colon cancer. In rectal cancer some studies displayed statistically significant results in favour of adjuvant chemotherapy: however, sufficient data are still unavailable to support adjuvant chemotherapy as standard treatment. On the contrary, postoperative radiotherapy is definitely effective in decreasing local relapses. Studies are underway on the combination of chemotherapy and radiotherapy in rectal cancer. In addition to systemic chemotherapy, portal infusion of cytotoxic drugs has been tested in colorectal cancer. Controlled studies are underway, but available results would not seem to support regional treatment. Recent improvement in the chemotherapy of advanced colorectal cancer has probably occurred through the pharmacologic modulation of 5-fluorouracil by leucovorin. If this will be confirmed, one will be able to resort to more effective multidrug regimens than those tested so far and an improvement in adjuvant chemotherapy may be anticipated too.
 ...
PMID:[Adjuvant chemotherapy of colorectal carcinoma]. 210 Sep 69

To examine the relation between alcoholic beverage consumption and risk of cancer of the right colon and rectum, 644 male cases and 992 male community controls were interviewed by telephone. The risks of cancer at these sites associated with alcohol consumption five years in the past were similar; using subjects with right colon cancer for reference, the adjusted relative risk (RR) of rectal cancer associated with five or more drinks per day was 0.9 (95% confidence limits = 0.4, 1.7). Alcohol consumption 20 years in the past was associated with a greater risk of rectal cancer (RR for five or more drinks per day = 1.8 [1.0, 3.3]). Analyses based on a community controls provided weaker evidence, consistent with previous findings, that heavy consumption of alcohol five years in the past, and possibly of beer in particular, was associated with moderately increased risk of colorectal cancer (RR of cancer of the right colon associated with consumption of five or more alcoholic drinks per day was 1.8 [1.0, 3.2], and of cancer of the rectum was 1.5 [0.9, 2.5]).
 ...
PMID:A case-control study of alcoholic beverage consumption in relation to risk of cancer of the right colon and rectum in men. 210 76


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>